The U.S. Court of Appeals for the Federal Circuit Tuesday upheld a federal district court ruling that Hospira Inc., now part of New York-based Pfizer Inc., didn't infringe two patents protecting a new way of making The Medicines Co.'s (MDCO) Angiomax (bivalirudin), but sent the case back to the lower court to determine whether the on-sale bar applies to a distribution contract MDCO had with Integrated Commercialization Solutions Inc. (ICS).